The serum VEGF level of the patients who were treated by dydrogesterone tablets in combination with TCRP was remarkably lower than that of the patients who was treated by TCRP only in six-month follow up, indicating the serum of the patients with endometrial polyps had high expression of VEGF and both therapies could effectively reduce the expression of serum VEGF. This evidence concerns the gene VEGFA and endometrial polyp.